Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2006-05-09
2006-05-09
Wang, Andrew (Department: 1635)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C536S023100, C536S024500, C435S006120, C435S069100, C435S320100, C435S375000
Reexamination Certificate
active
07041654
ABSTRACT:
The present invention relates to the tumor-specific expression of heterologous polynucleotides, particularly genes encoding cytotoxic products, under the control of transcriptional regulatory sequences. Particularly preferred transcriptional regulatory sequences comprise H19, IGF-1 and IGF-2 P4 transcriptional regulatory sequences, and variants thereof. The present invention also provides expression constructs and methods of administering such expression constructs. The compositions and methods of the invention are useful for the treatment of proliferative disorders, particularly cancer.
REFERENCES:
patent: 5998205 (1999-12-01), Hallenbeck et al.
patent: 714867 (1996-04-01), None
patent: 2725213 (1996-04-01), None
patent: WO 94/13824 (1994-06-01), None
patent: WO 95/05835 (1995-03-01), None
patent: WO 95/14101 (1995-05-01), None
patent: WO 95/24503 (1995-09-01), None
patent: WO 96/05321 (1996-02-01), None
patent: WO 99/18195 (1999-04-01), None
patent: WO 01/23004 (2001-04-01), None
Boccehetta et al. Epidemiology and molecular pathology at crossroads to establish causation: molecular mechanisms of malignant transformation. Aug., 2004. Oncogene (23):6484-91.
Morris et al. Adenoviral—mediated gene transfer to bladder in vivo Aug., 1994. Journal of Urology (152):506-509.
Webster's II new Riverside university dictionary. 1994 The Riverside Publishing Company p. 933.
The CancerWEB Project, Published at the Dept. of Medical Oncology, University of Newcastle upon Tyne (cancerweb.ncl.ac.uk). Nov., 1997.
Anderson, 1998, “Human gene therapy”, Nature 392:25-30.
Ariel et al. 1997, “The product of the imprinted H19 gene is an oncofetal RNA”, J. Clin. Pathol. Mol. Pathol. 50:34-44.
Branch, 1998, “A Good antisense molecule is hard to find”, TIBS 23:45-50.
Brannan et al., 1990, “The product of the H19 gene may function as an RNA”, Mol. Cell. Biol. 10:28-36.
Brunkow and Tilghman, 1991, “Ectopic expression of the H19 gene in mice causes prenatal lethality”, Genes & Dev. 5:1092-1101.
Crooke , 1998, “Basic principles of antisense therapeutics”, in:Antisense Research and Application, Cooke, ed., Springer-Verlag, pp. 1-50.
Crooke et al., 1997, “A roundtable on the state of the industry”, Nature Biotechnol. 15:522.
Davis et al., 1987, “Expresion of a single transfected cDNA converts fibroblasts to myoblasts”, Cell 51:987-1000.
DeGroot et al., 1994, “Genetic imprinting in human embryogenesis H19 and IGF2 gene expression”, Trophoblast Res. 8:285-302.
Elkin et al., 1995, “The expression of the imprinted H19 and IGF-2 genes in human bladder carcinoma”, FEBS Lett. 374:57-61.
Glassman et al, 1996, “Relaxation of imprinting in carcinogenesis”, Cancer Genet. Cytogenet. 89:69-73.
Gura, 1995, “Antisense has growing pains”, Science 270:575-577.
Hao et al., 1993, “Tumour-suppressor activity of H19 RNA”, Nature 365:764-767.
Holthuizen et al., 1993, “Transcriptional regulation of the major promoters of the human IGF-II gene”, Mol. Reprod. Dev. 35:391-393.
Hu et al., 1997, “Genomic deletion of an imprint maintenance element abolishes imprinting of both insulin-like growth factor II and H19”, J. Biol. Chem. 272:20715-20720.
Huber et al., 1991, “Retroviral—mediated gene therapy for the treatment of hepatocellular carcinoma: an innovative approach for cancer therapy”, Proc. Natl. Acad. Sci. USA 88:8039-8043.
Hurst et al., 1996, “Imprinted genes have few small introns”, Nature Genetics 12:234-237.
Kaneko et al. 1995, “Adenovirus—mediated gene therapy of hepatocellular carcinoma using cancer-specific gene expression”, Cancer Res. 55:5283-5287.
Leighton et al., 1995, “Disruption of imprinting caused by deletion of theH19gene region in mice”, Nature 375:34-39.
Lustig-Yariv et al., 1997, “The expression of the imprinted genes H19 and IGF-2 in choriocarcinoma cell lines. Is H19 a tumor suppressor gene?”, Oncogene 15:169-177.
Ogawa et al., 1993, “Relaxation of insulin-like growth factor II gene imprinting implicated in Wilms' tumour”, Nature 362:747-749.
Orkin et al., 1995, “Report and recommendations of the panel to assess the NIH investment in research on gene therapy”, pp. 1-23.
Osaki et al., 1994, “Gene therapy for carcinoembryonic antigen-producing human lung cancer cells by cell type-specific expression of herpes simplex virus thymidine kinase gene”, Cancer Res. 54:5258-5261.
Pachnis et al., 1984, “Locus unlinked to α-fetoprotein under the control of the murine raf and Rif genes”, Proc. Natl. Acad. Sci. USA 81:5523-5527.
Pfeiffer et al., 1996, “The structural H19 gene Is required for transgene imprinting”, Proc. Natl. Acad. Sci. USA 93:13876-13883.
Poirier et al., 1991, “The murine H19 gene is activated during embryonic stem cell differentiationin vitroand at the time of implantation in the developing embryo”, Devel. 113:1105-1114.
Rachmilewitz et al., 1992, “Transcription of the H19 gene in differentiating cytotrophoblasts from human placenta”, Mol. Reprod. Dev. 32:196-202.
Rainier et al., 1993, “Relaxation of imprinted genes in human cancer”, Nature 362:747-749.
Seo et al., 1998, “Different protein-binding patterns in the P3 promoter region of the human insulin-like growth factor II gene in the human liver cirrhosis and hepatocellular carcinoma tissues”, J. Korean Med. Sci. 13:171-178.
Vile et al., 1993, “Use of tissue-specific expression of the herpes simplex virus thymidine kinase gene to inhibit growth of established murine melanomas following direct intratumoral injection of DNA”, Cancer Res. 53:3860-3864.
Wilkins, 1988, “Genomic imprinting and carcinogenesis”, Lancet, Feb. 13;1(8581):329-31.
Xu et al., 1996, “Tissue specific growth suppression and chemosensitivity promotion in human hepatocellular carcinoma cells by retroviral—mediated transfer of the wild-type p53 gene”, Hepatol. 24:1264-1268.
Alemany et al. Replicative adenoviruses for cancer therapy. Nat Biotechnol. Jul. 2000;18(7):723-7. Review.
Atencio et al. A phase 1 clinical trial of intro-arterial adenovirus p53 (SCH 58500) gene therapy for colorectal tumors metastatic to the liver. Molecular Therapy May 2001; 3(5):S309.
Burchin et al. Adenovirus—mediated regulable target gene expression in vivo. Proc Natl Acad Sci U S A. Jan. 19, 1999;96(2):355-60.
Gomez-Navarro et al. Gene therapy for cancer. Eur J Cancer. Jun. 1999;35(6):867-85. Review.
Jeremy W. Fry and Kathryn J. Wood (1999) Gene therapy: potential application in clinical transplantation. Exp. Rev. Mol. Med. Jun. 8, http://www-ermm.cbcu.cam.ac.uk/99000691h.htm.
Kusumanto et al, Phase III comparison of intramuscular delivery of ANG1 (a Vascular Endothelial Growth Factor containing plasmid) with placebo in diabetic patients with critical limb ischaemia. Molecular Therapy May 2001; 3(5):S73.
Marshall E. Gene therapy's growing pains. Science. Aug. 25, 1995;269(5227):1050, 1052-5.
Oyama et al. Intravesical and intravenous therapy of human bladder cancer by the herpes vector G207. Hum Gene Ther. Aug. 10, 2000;11(12):1683-93.
Pagliaro LC. Gene therapy for bladder cancer. World J Urol. Apr. 2000;18(2):148-51, Review.
Ramachandra et al. Re-engineering adenovirus regulatory pathways to enhance oncolytic specificity and efficacy. Nat Biotechnol. Nov. 2001;19(11):1035-41.
Ramesh et al. Successful treatment of primary and disseminated human lung cancers by systemic delivery of tumor suppressor genes using an improved liposome vector. Mol Ther. Mar. 2001;3(3):337-50.
Sayre et al. Gene therapy with systemically delivered IL-2 based plasmid/lipid complexes. Molecular Therapy May 2001; 3(5):S384.
Ayesh et al, “Inhibition of tumor growth by DT-A expressed under the control of IGF2 P3 and P4 promoter sequences”,Mol Th
Ayesh Suhail
Hochberg Abraham
Ashen Jon B.
Browdy and Neimark PLLC
Wang Andrew
Yissum Research Development Company of the Hebrew University of
LandOfFree
Methods and compositions for inducing tumor-specific... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and compositions for inducing tumor-specific..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and compositions for inducing tumor-specific... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3612639